|Ms. Leslie Auld||Sr. VP & CFO||233.94k||N/A||N/A|
|Dr. Klaus Paulini||Pres, CEO & Director||N/A||N/A||N/A|
|Dr. Nicola Ammer||Chief Medical Officer & VP of Clinical Devel.||N/A||N/A||N/A|
|Mr. Olaf Althaus||GM & MD||N/A||N/A||N/A|
|Ms. Amélie Métivier||Assistant Sec.||N/A||N/A||N/A|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.